BeOne Medicines Ltd. (ONC) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone. Welcome to B1 Medicine's Q4 and full year 2025 earnings call webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. At this time, I would like to turn the call over to the company. Hello and welcome. Thanks for joining us today. I'm Dan Maller, head of investor relations at B1 Medicines. Before we begin, please note that you can find additional materials, including a replay of today's webcast and presentation on the investor relations section of our website, ir.b1medicines.com. I would like to remind all participants that during this call, we may make forward-looking statements regarding, among other things, the company's future prospects and business strategy. Actual results may differ materially from those indicated in the forward-looking statements as a result of various factors, including those risks discussed in our most recent periodic report filed with the SEC. Please also carefully review the forward-looking statements disclaimer on the slide deck that accompanies this presentation. Reconciliations between GAAP and non-GAAP financial measures discussed on this call are provided in the appendix to our presentation, which is posted to our investor relations website, along with our earnings release. And all information in this presentation is as of the date of this presentation, we undertake no duty to update such information unless required by law. Now turning to today's call is outlined on slide three. John Euler, our co-founder, chairman, and CEO, will provide a business update, including commentary on our foundational CLL franchise. Aaron Rosenberg, our CFO, will provide an update on our fourth quarter financial results and 2026 financial guida...